A new model of active specific immunotherapy using interleukin-1 and sonicated tumor supernatant in murine tumor system.
The possibility of active specific immunotherapy using interleukin-1 (IL-1) plus sonicated tumor supernatant (SS) was examined in a murine tumor model. The growth of intraperitoneally or subcutaneously inoculated plasmacytoma MOPC104E, which is syngeneic to BALB/c mice, was significantly suppressed by intraperitoneal pretreatment with IL-1 and SS from MOPC104E cells (MOPC-SS), on days 10, 7, and 4 before tumor inoculation. Pretreatment with IL-1 plus MOPC-SS or MethA-SS (SS from MethA cells) suppressed the growth of subcutaneous tumor of only the corresponding tumor cells, indicating the development of tumor-specific immunity in vivo. The splenic cells of immunized mice with IL-1 and MOPC-SS showed tumor neutralizing activity. However, their tumor neutralizing activity was abrogated when they were treated in vitro with anti-Thy1.2 or anti-L3T4 plus complement. Moreover, when combined with indomethacin per oral, IL-1 plus MOPC-SS significantly suppressed the growth of established subcutaneous tumor and prolonged survival of post-operative mice. These results suggest that this new type of active specific immunotherapy could be a useful method for cancer immunotherapy, especially when combined with oral indomethacin.
Moriguchi
Y
Y
First Department of Surgery, Faculty of Medicine, Kyoto University, Japan.
Kan
N
N
Okino
T
T
Harada
T
T
Yamasaki
S
S
Ichinose
Y
Y
Li
L
L
Sugie
T
T
Imamura
M
M
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000627:therapeutic use*; D011232:Chemical Precipitation; D004305:Dose-Response Relationship, Drug; D005354:Fibrosarcoma / Q000737:chemistry / Q000628:therapy; D007375:Interleukin-1 / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000737:chemistry / Q000276:immunology* / Q000628:therapy*; D010954:Plasmacytoma / Q000737:chemistry / Q000628:therapy; D016016:Proportional Hazards Models; D013010:Sonication; D013154:Spleen / Q000166:cytology; D016019:Survival Analysis; D014407:Tumor Cells, Cultured; D014611:Vaccination / Q000379:methods*
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D007375:Interleukin-1; D007376:Interleukin-2